20/20 GeneSystems Inc. products

20/20 GeneSystems developed PAULA’s Test, a blood test for early detection of lung cancer. It is available in the USA through licensed medical professionals. Testing is performed at 20/20’s CLIA licensed laboratory, Genesys Biolabs (CLIA Lic# 21D2037411). PAULA’s Test is meant for use in patients at high risk of lung cancer due to long term smoking. PAULA’s Test can help detect lung cancer in patients without symptoms, even at the earliest stages. While lung screening using Low Dose CT scans is available today at many hospitals, many patients do not meet the eligibility criteria to receive screening tests. For patients who are at risk for lung cancer but either do not meet eligibility or who choose not to undergo annual CT scans, PAULA’s Test may be an option for a test for early detection.

Comprehensive health screening, something common in many countries outside of the U.S. has been something that is rarely accessible for most Americans. By placing a high priority on early detection, most cancers can be survivable when detected early enough to be surgically removed. Now, 20/20 is bringing a new blood test to the U.S. which can detect the possible presence of five or more cancer types using a standard blood specimen.